Assertio Therapeutics
LEI 549300L2A9NTF1JVDP20
Upgrade to Premium features
Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market
Get access-
Full access to the largest bond database
Bond parameters,
prospectuses -
Seamless
Data exportAnalyze the data in the most efficient way
-
Bond pricing
Current & historical quotes from 400+ stock exchanges & OTC market
-
Smart risk assessment
Credit ratings, financial reports
Trading Schedule Issuer map
Quotes
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Profile
|
As a result of the Assertio Reorganization, Assertio Holdings became the successor issuer to Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc., formerly Depomed Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States.
|
General information
-
Organization nameAssertio Therapeutics, Inc.
-
Organization statusLiquidated
-
AddressC/O The Corporation Trust Company Corporation Trust Center 1209 Orange Street Wilmington, USA, 19801
-
Phone224-419-7106
-
Previous organization nameDepomed (to 14/08/2018)
IFRS/US GAAP reports
| 2020 | |
| 2019 | |
| 2018 | |
| 2017 | |
| 2016 | |
| 2015 | |
| 2014 | |
Stocks
General information
-
Organization nameAssertio Therapeutics, Inc.
-
Organization statusLiquidated
-
AddressC/O The Corporation Trust Company Corporation Trust Center 1209 Orange Street Wilmington, USA, 19801
-
Phone224-419-7106
-
Previous organization nameDepomed (to 14/08/2018)
Codes
-
LEI549300L2A9NTF1JVDP20
-
SIC2834 PHARMACEUTICAL PREPARATIONS
-
CIK0001005201









